Integra LifeSciences (NASDAQ:IART) Stock Price Breaks Above Two Hundred Day Moving Average – Here’s What Happened

Integra LifeSciences Holdings Corporation (NASDAQ:IART) crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $14.10 and traded as high as $15.15. Integra LifeSciences shares last traded at $14.82, with a volume of 1,174,234 shares.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on IART shares. Citigroup reiterated an “outperform” rating on shares of Integra LifeSciences in a research report on Thursday, October 22nd. Wells Fargo & Company set a $13.00 price target on Integra LifeSciences and gave the stock an “equal weight” rating in a research report on Thursday, October 22nd. BMO Capital Markets reissued a “market perform” rating and set a $14.00 target price (down from $15.00) on shares of Integra LifeSciences in a research note on Thursday, October 22nd. Zacks Research downgraded Integra LifeSciences from a “hold” rating to a “strong sell” rating in a research report on Monday, October 26th. Finally, Weiss Ratings raised shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d+)” rating in a research note on Monday, October 26th. Two analysts have rated the stock with a Buy rating, five have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average price target of $16.12.

Integra LifeSciences Stock Up 8.7%

The firm’s 50 day simple moving average is $14.67 and its 200-day simple moving average is $14.10. The company has a market cap of $1.15 billion, a price-to-earnings ratio of 87.18, a P/E/G ratio of 0.53 and a beta of 1.28. The company has a debt-to-equity ratio of 1.67, a current ratio of 3.62 and a quick ratio of 2.21.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Wednesday, October 21st. The life sciences company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.56 by $0.03. The company had revenue of $411.18 million during the quarter, compared to analysts’ expectations of $413.16 million. Integra LifeSciences had a return on equity of 18.63% and a net margin of 0.79%. During the same quarter in the previous year, the business earned ($0.07) earnings per share. As a group, sell-side analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.34 earnings per share for the current year.

Hedge Funds Weigh In On Integra LifeSciences

Institutional investors have recently bought and sold shares of the company. Inspire Investing LLC grew its stake in Integra LifeSciences by 5.2% in the 3rd quarter. Inspire Investing LLC now owns 39,168 shares of the life sciences company’s stock valued at $638,000 after acquiring an additional 1,929 shares during the last quarter. Commonwealth Equity Services LLC grew its holdings in Integra LifeSciences by 1.9% during the 3rd quarter. Commonwealth Equity Services LLC now owns 152,837 shares of the life sciences company’s stock valued at $2,488,000 after buying an additional 2,889 shares during the last quarter. Sequoia Financial Advisors LLC increased its position in Integra LifeSciences by 27.4% during the first quarter. Sequoia Financial Advisors LLC now owns 14,233 shares of the life sciences company’s stock worth $134,000 after buying an additional 3,059 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new stake in shares of Integra LifeSciences in the second quarter valued at $82,000. Finally, Integrated Wealth Concepts LLC purchased a new stake in Integra LifeSciences during the 2nd quarter worth about $84,000. 84.78% of the stock is owned by institutional investors and hedge funds.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, orthopedics and wound care. Its portfolio includes medical devices, surgical instruments and regenerative tissue technologies designed to help healthcare professionals treat complex conditions and support patient recovery.

Integra’s neurosurgical products include dural repair products, cerebrospinal fluid management systems, cranial stabilization devices and specialized surgical instruments.